Earnings To Watch: Fortrea (FTRE) Reports Q4 Results Tomorrow

SelfRugger · 2026-03-25T06:57:05+00:00

Fortrea Holdings is set to report its Q4 earnings, with expectations of a 4.3% revenue decline year on year. Despite a strong performance last quarter, analysts predict continued challenges as the stock has seen a significant downturn recently.

SelfRugger

2026-03-25 06:57:05

Abstract generation in progress

Earnings To Watch: Fortrea (FTRE) Reports Q4 Results Tomorrow

Adam Hejl

Thu, February 26, 2026 at 1:56 AM GMT+9 2 min read

In this article:

FTRE

-0.53%

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be announcing earnings results tomorrow morning. Here’s what to expect.

Fortrea beat analysts’ revenue expectations last quarter, reporting revenues of $701.3 million, up 3.9% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.

Is Fortrea a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Fortrea’s revenue to decline 4.3% year on year, a further deceleration from the 1.8% decrease it recorded in the same quarter last year.

Fortrea Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Fortrea has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Fortrea’s peers in the drug development inputs & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. UFP Technologies delivered year-on-year revenue growth of 3.4%, meeting analysts’ expectations, and Medpace reported revenues up 32%, topping estimates by 3.3%. Medpace traded down 15.9% following the results.

Read our full analysis of UFP Technologies’s results here and Medpace’s results here.

Investors in the drug development inputs & services segment have had fairly steady hands going into earnings, with share prices down 1.1% on average over the last month. Fortrea is down 36.8% during the same time and is heading into earnings with an average analyst price target of $16.44 (compared to the current share price of $10.98).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.